ImmunityBio, Inc. (NASDAQ: IBRX), a prominent immunotherapy company, has announced the execution of an $80 million equity financing agreement with two institutional investors. This financing is structured as a registered direct offering, involving the issuance of common stock and warrants to purchase additional shares of ImmunityBio. The transaction is expected to generate gross proceeds of approximately $80 million, before the deduction of placement agent fees and related expenses, with the potential for an additional $96 million if the warrants are fully exercised. Piper Sandler & Co. is serving as the exclusive placement agent for this offering. The securities are being offered under ImmunityBio's automatic shelf registration statement on Form S-3.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.